Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

TheMotleyFool

0 0

Is Gilead Sciences a Buy After Its Disappointing Q2 Results?

Gilead Sciences (NASDAQ: GILD) beat Wall Street estimates when the big biotech announced its first-quarter results in late April. But the streak didn't last long.

Last week, Gilead announced second-quarter results that were below analysts' expectations. Its revenue declined 10.5% year over year, with adjusted earnings plunging 36%. But is Gilead stock now a buy after its disappointing Q2 results?

Image source: Getty Images.

Source Fool.com

Like: 0

GILD

Share